By Matt Hoffman – CGTlive –
As 2025 comes to a close, CGTLive has looked back on some of the most-read and most impactful FDA regulatory decisions and news in the cell and gene therapy space. These approvals and regulatory actions marked major progress for patients with previously limited or no treatment options, and also reflected increasing FDA flexibility in areas of rare disease, novel delivery mechanisms, and advanced biologics manufacturing.
